South Street Advisors LLC Buys 7,060 Shares of Eli Lilly And Co (NYSE:LLY)

South Street Advisors LLC grew its stake in Eli Lilly And Co (NYSE:LLY) by 7.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,140 shares of the company’s stock after purchasing an additional 7,060 shares during the period. Eli Lilly And Co makes up about 3.2% of South Street Advisors LLC’s portfolio, making the stock its 18th biggest position. South Street Advisors LLC’s holdings in Eli Lilly And Co were worth $10,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of LLY. Trust Department MB Financial Bank N A increased its holdings in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after purchasing an additional 82 shares during the period. Wealthquest Corp increased its holdings in Eli Lilly And Co by 1.5% during the 1st quarter. Wealthquest Corp now owns 6,307 shares of the company’s stock worth $818,000 after purchasing an additional 94 shares during the period. Lourd Capital LLC increased its holdings in Eli Lilly And Co by 2.7% during the 2nd quarter. Lourd Capital LLC now owns 3,723 shares of the company’s stock worth $412,000 after purchasing an additional 97 shares during the period. Meridian Wealth Advisors LLC increased its holdings in Eli Lilly And Co by 6.1% during the 1st quarter. Meridian Wealth Advisors LLC now owns 1,746 shares of the company’s stock worth $227,000 after purchasing an additional 100 shares during the period. Finally, Webster Bank N. A. increased its holdings in Eli Lilly And Co by 5.6% during the 2nd quarter. Webster Bank N. A. now owns 1,900 shares of the company’s stock worth $210,000 after purchasing an additional 100 shares during the period. 79.50% of the stock is owned by institutional investors and hedge funds.

Shares of Eli Lilly And Co stock traded up $1.19 during trading on Friday, reaching $111.70. The company’s stock had a trading volume of 1,644,142 shares, compared to its average volume of 3,743,069. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. The stock has a market capitalization of $108.05 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.91 and a beta of 0.20. Eli Lilly And Co has a 1-year low of $97.84 and a 1-year high of $132.13. The company has a 50-day moving average price of $111.06.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a return on equity of 57.99% and a net margin of 33.76%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 EPS. As a group, equities analysts predict that Eli Lilly And Co will post 5.71 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.31%. Eli Lilly And Co’s payout ratio is 46.49%.

Several brokerages have issued reports on LLY. Goldman Sachs Group began coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They set a “buy” rating and a $135.00 target price on the stock. Edward Jones raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research report on Tuesday, April 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $143.00 target price on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Finally, Barclays reaffirmed a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $123.49.

In other news, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joshua L. Smiley acquired 426 shares of the stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average cost of $118.03 per share, with a total value of $50,280.78. Following the transaction, the chief financial officer now directly owns 30,410 shares in the company, valued at $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is owned by company insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Put Option Volume

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.